Masimo vs. Apple: Voluntary Dismissal in Heart Rate Monitor Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Masimo Corp. v. Apple Inc. |
| Case Number | 25-1305 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Dec 2024 – Feb 2025 69 days |
| Outcome | Voluntary Dismissal – Each side bear own costs |
| Patents at Issue | |
| Accused Products | Apple Watch (seamlessly embedded heart rate monitor) |
Case Overview
The Parties
⚖️ Plaintiff
Global leader in non-invasive patient monitoring technology, specializing in pulse oximetry and continuous health monitoring.
🛡️ Defendant
Tech giant known for its Apple Watch, a central product in wearable health technology, integrating heart rate, blood oxygen, and ECG capabilities.
Patents at Issue
This case involved U.S. Patent No. 10,076,257 B2, covering a seamlessly embedded heart rate monitor technology designed to integrate continuous, non-intrusive heart rate sensing into wearable devices.
- • US 10,076,257 B2 — Seamlessly embedded heart rate monitor technology for wearable devices
Developing a wearable health product?
Check if your heart rate monitoring design might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit dismissed Case No. 25-1305 pursuant to Fed. R. App. P. 42(b) — the federal rule governing voluntary dismissal of appeals upon stipulation of the parties. The court’s order is clear and unambiguous:
“The parties having so agreed, it is ordered that: (1) The proceeding is DISMISSED under Fed. R. App. P. 42(b). (2) Each side shall bear their own costs.”
No damages were awarded. No injunctive relief was granted or denied. No merits ruling was issued. The mutual cost-bearing arrangement — each side responsible for its own expenses — is a hallmark of negotiated resolution, distinguishing this outcome from a unilateral withdrawal that might signal one party’s weakness.
Key Legal Issues
The case was categorized under invalidity/cancellation action, meaning the appellate dispute involved a challenge to the patentability of U.S. Patent No. 10,076,257 B2. In the broader Masimo-Apple litigation ecosystem, Apple has pursued multiple validity challenges against Masimo’s patent portfolio, including through PTAB IPR proceedings.
Because the case resolved before any Federal Circuit merits ruling, no claim construction determinations, obviousness analyses, or enablement findings were issued in this proceeding. The absence of a substantive ruling preserves ambiguity around the patent’s validity status as adjudicated at this appellate level — a meaningful consideration for any party evaluating the enforceability of U.S. 10,076,257 B2 going forward.
Drafting a patent for health tech?
Learn from this case. Use AI to draft stronger claims for wearable monitoring.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in wearable health technology design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in wearable biosensor space
- See which companies are most active in health tech patents
- Understand claim construction patterns for continuous monitoring
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own wearable device.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Seamlessly embedded heart rate monitors
US 10,076,257 B2
Patent at issue, invalidity challenge
Design-Around Options
Potentially available for many sensor integrations
✅ Key Takeaways
For Patent Attorneys & Litigators
Voluntary Federal Circuit dismissal under Rule 42(b) generates no precedent and leaves the underlying validity record operative.
Search related case law →Multi-forum patent campaigns require continuous cost-benefit analysis at each appellate stage.
Explore precedents →For R&D Teams
Seamlessly embedded heart rate monitoring architectures remain IP-sensitive; design documentation should support design-around evidence.
Start FTO analysis for my product →Validate FTO status of U.S. 10,076,257 B2 with qualified patent counsel before product launch.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.